Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bitopertin in adults with erythropoietic protoporphyria or X-linked protoporphyria
ACTRN12622000799752Phase 2Completed
- Sponsor
- Disc Medicine
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (3 arms), sponsored by Disc Medicine. Primary endpoint: Percent change from baseline in erythrocyte metal-free protoporphyrin IX. Started Sep 2022; status: completed.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on ACTRN12622000799752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000799752.